Whether medication, metabolic support, or a combination of strategies makes sense, our role is to help you move forward with clarity and confidence
Long-term pharmacovigilance planning, adverse event characterization, real-world evidence generation, and post-marketing surveillance strategies are therefore not secondary considerations, but essential pillars of responsible therapeutic development
The PCAC review scheduled for July 2026 is the next formal regulatory review point
The risk of granulomas can be significantly reduced by using proper injection technique and following post-injection care instructions, including massage
Infant feeding, growth, and behavior should also be observed, especially in the early weeks of exposure